MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited Net Income 2011-2026 | VNRX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.3 M | -35.7 M | -30.6 M | -27 M | - | -16.1 M | -18 M | -14.8 M | -11.9 M | -9.53 M | -8.21 M | -3.71 M | - | -13 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13 K | -35.7 M | -16.9 M |
Quarterly Net Income VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.38 M | -6.28 M | -5.42 M | - | -5.87 M | -7.06 M | -8.47 M | - | -8.45 M | -9.55 M | -8.87 M | - | -7.81 M | -7.73 M | -7.72 M | - | -7.18 M | -5.57 M | -6.13 M | - | -4.34 M | -5.04 M | -5.86 M | - | -4.18 M | -4.16 M | -4.2 M | - | -4.48 M | -4.59 M | -4.65 M | - | -3.89 M | -3.46 M | -3.35 M | - | -3.48 M | -2.95 M | -2.49 M | - | -2.96 M | -1.87 M | -2.01 M | - | -5.89 M | 817 K | -2.19 M | - | -926 K | -1.05 M | -908 K | - | -2.61 M | -931 K | -802 K | - | -1.69 M | -640 K | -335 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 817 K | -9.55 M | -4.28 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Interpace Biosciences
IDXG
|
6.7 M | $ 1.71 | 0.73 % | $ 7.5 M |  USA |
 |
Illumina
ILMN
|
-1.22 B | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
Biomerica
BMRA
|
-4.97 M | $ 2.13 | -2.74 % | $ 4.89 M | USA |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M |  Israel |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
NeoGenomics
NEO
|
-108 M | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-208 M | $ 104.91 | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
-548 M | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
Aspira Women's Health
AWH
|
-27.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
-35.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
OPKO Health
OPK
|
14 M | $ 1.15 | 2.68 % | $ 798 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Personalis
PSNL
|
-81.3 M | $ 7.61 | 4.82 % | $ 451 M | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
1.36 B | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
IDEXX Laboratories
IDXX
|
1.06 B | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-112 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Medpace Holdings
MEDP
|
451 M | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Senseonics Holdings
SENS
|
-69.1 M | $ 6.62 | 2.16 % | $ 276 M | USA |
 |
Sotera Health Company
SHC
|
77.9 M | $ 13.88 | 2.81 % | $ 3.94 B | USA |
 |
Agilent Technologies
A
|
1.21 B | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
20.9 M | $ 31.72 | -4.52 % | $ 1.61 B | USA |
 |
DarioHealth Corp.
DRIO
|
-41.7 M | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
-416 M | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
Myriad Genetics
MYGN
|
-366 M | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
Psychemedics Corporation
PMD
|
-4.15 M | - | -1.84 % | $ 15.3 M | USA |
 |
Neuronetics
STIM
|
-39 M | $ 1.6 | 10.34 % | $ 106 M | USA |
 |
QIAGEN N.V.
QGEN
|
83.6 M | - | - | $ 10.6 B |  Niderland |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-11.5 M | $ 3.48 | 0.87 % | $ 1.87 M | USA |
 |
Thermo Fisher Scientific
TMO
|
6.7 B | $ 478.12 | 0.79 % | $ 180 B | USA |
 |
Celcuity
CELC
|
-112 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
876 M | $ 264.42 | 0.54 % | $ 22 B | USA |